Development and clinical deployment of a smartphone-based visual field deep learning system for glaucoma detection

Abstract By 2040, ~100 million people will have glaucoma. To date, there are a lack of high-efficiency glaucoma diagnostic tools based on visual fields (VFs). Herein, we develop and evaluate the performance of ‘iGlaucoma’, a smartphone application-based deep learning system (DLS) in detecting glauco...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fei Li, Diping Song, Han Chen, Jian Xiong, Xingyi Li, Hua Zhong, Guangxian Tang, Sujie Fan, Dennis S. C. Lam, Weihua Pan, Yajuan Zheng, Ying Li, Guoxiang Qu, Junjun He, Zhe Wang, Ling Jin, Rouxi Zhou, Yunhe Song, Yi Sun, Weijing Cheng, Chunman Yang, Yazhi Fan, Yingjie Li, Hengli Zhang, Ye Yuan, Yang Xu, Yunfan Xiong, Lingfei Jin, Aiguo Lv, Lingzhi Niu, Yuhong Liu, Shaoli Li, Jiani Zhang, Linda M. Zangwill, Alejandro F. Frangi, Tin Aung, Ching-yu Cheng, Yu Qiao, Xiulan Zhang, Daniel S. W. Ting
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Acceso en línea:https://doaj.org/article/481e146d7ee14aa8bb8e0910e851c4af
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract By 2040, ~100 million people will have glaucoma. To date, there are a lack of high-efficiency glaucoma diagnostic tools based on visual fields (VFs). Herein, we develop and evaluate the performance of ‘iGlaucoma’, a smartphone application-based deep learning system (DLS) in detecting glaucomatous VF changes. A total of 1,614,808 data points of 10,784 VFs (5542 patients) from seven centers in China were included in this study, divided over two phases. In Phase I, 1,581,060 data points from 10,135 VFs of 5105 patients were included to train (8424 VFs), validate (598 VFs) and test (3 independent test sets—200, 406, 507 samples) the diagnostic performance of the DLS. In Phase II, using the same DLS, iGlaucoma cloud-based application further tested on 33,748 data points from 649 VFs of 437 patients from three glaucoma clinics. With reference to three experienced expert glaucomatologists, the diagnostic performance (area under curve [AUC], sensitivity and specificity) of the DLS and six ophthalmologists were evaluated in detecting glaucoma. In Phase I, the DLS outperformed all six ophthalmologists in the three test sets (AUC of 0.834–0.877, with a sensitivity of 0.831–0.922 and a specificity of 0.676–0.709). In Phase II, iGlaucoma had 0.99 accuracy in recognizing different patterns in pattern deviation probability plots region, with corresponding AUC, sensitivity and specificity of 0.966 (0.953–0.979), 0.954 (0.930–0.977), and 0.873 (0.838–0.908), respectively. The ‘iGlaucoma’ is a clinically effective glaucoma diagnostic tool to detect glaucoma from humphrey VFs, although the target population will need to be carefully identified with glaucoma expertise input.